Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Atara Biotherapeutics (ATRA) Other Non Operating Income (2022 - 2025)

Atara Biotherapeutics filings provide 4 years of Other Non Operating Income readings, the most recent being -$49000.0 for Q4 2025.

  • On a quarterly basis, Other Non Operating Income rose 44.94% to -$49000.0 in Q4 2025 year-over-year; TTM through Mar 2026 was -$23000.0, a 105.12% decrease, with the full-year FY2025 number at -$34000.0, down 106.44% from a year prior.
  • Other Non Operating Income hit -$49000.0 in Q4 2025 for Atara Biotherapeutics, down from $4000.0 in the prior quarter.
  • In the past five years, Other Non Operating Income ranged from a high of $555000.0 in Q3 2024 to a low of -$309000.0 in Q3 2022.
  • Median Other Non Operating Income over the past 4 years was -$19500.0 (2023), compared with a mean of -$28312.5.
  • The widest YoY moves for Other Non Operating Income: up 2155.56% in 2024, down 641.67% in 2024.
  • Atara Biotherapeutics' Other Non Operating Income stood at -$69000.0 in 2022, then soared by 82.61% to -$12000.0 in 2023, then tumbled by 641.67% to -$89000.0 in 2024, then surged by 44.94% to -$49000.0 in 2025.
  • The last three reported values for Other Non Operating Income were -$49000.0 (Q4 2025), $4000.0 (Q3 2025), and $22000.0 (Q2 2025) per Business Quant data.